NYSE:CC - Chemours Stock Price, Forecast & News

Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Chemours declared a quarterly dividend on Wednesday, October 30th. Stockholders of record on Friday, November 15th will be paid a dividend of $0.25 per share on Monday, December 16th. This represents a $1.00 annualized dividend and a dividend yield of 5.73%. The ex-dividend date of this dividend is Thursday, November 14th. View Chemours' Dividend History.

Chemours Co (NYSE:CC) released its earnings results on Monday, November, 4th. The specialty chemicals company reported $0.59 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.56 by $0.03. The specialty chemicals company earned $1.39 billion during the quarter, compared to analysts' expectations of $1.40 billion. Chemours had a return on equity of 58.38% and a net margin of 7.24%. The company's revenue was down 14.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.49 earnings per share. View Chemours' Earnings History.

Chemours is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Chemours.

Chemours issued an update on its FY19 earnings guidance on Monday, November, 4th. The company provided EPS guidance of $2.37-3.08 for the period, compared to the Thomson Reuters consensus estimate of $2.47.

12 brokerages have issued 12 month target prices for Chemours' shares. Their forecasts range from $14.50 to $42.00. On average, they anticipate Chemours' share price to reach $23.15 in the next year. This suggests a possible upside of 32.6% from the stock's current price. View Analyst Price Targets for Chemours.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chemours in the last year. There are currently 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Chemours.

News stories about CC stock have trended positive this week, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Chemours earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave news stories about the specialty chemicals company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Chemours.

Chemours saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 16,370,000 shares, a decrease of 5.9% from the December 15th total of 17,390,000 shares. Based on an average trading volume of 2,490,000 shares, the short-interest ratio is presently 6.6 days. Approximately 10.1% of the shares of the company are short sold. View Chemours' Current Options Chain.

Some companies that are related to Chemours include Johnson Matthey (JMPLY), Huntsman (HUN), W. R. Grace & Co (GRA), Ashland Global (ASH), KURARAY CO LTD/ADR (KURRY), Univar (UNVR), Balchem (BCPC), Ingevity (NGVT), Olin (OLN), Innospec (IOSP), PQ Group (PQG), GCP Applied Technologies (GCP), Livent (LTHM), Innophos (IPHS) and Hawkins (HWKN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chemours investors own include E I Du Pont De Nemours And Co (DD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Alibaba Group (BABA), DowDuPont (DWDP), Johnson & Johnson (JNJ), Energy Transfer LP Unit (ET) and Intel (INTC).

Chemours' stock is owned by many different of retail and institutional investors. Top institutional shareholders include DNB Asset Management AS (0.40%), Heritage Investors Management Corp (0.08%), Nisa Investment Advisors LLC (0.05%), State of Alaska Department of Revenue (0.02%), Boenning & Scattergood Inc. (0.01%) and FNY Investment Advisers LLC (0.00%). Company insiders that own Chemours stock include Amy Trojanowski, Bradley J Bell, David C Shelton, E Bryan Snell, Erich Parker, Mark Newman, Mark P Vergnano, Mary B Cranston, Paul Kirsch, Richard H Brown and Susan M Kelliher. View Institutional Ownership Trends for Chemours.

CC stock was sold by a variety of institutional investors in the last quarter, including Boenning & Scattergood Inc., State of Alaska Department of Revenue and Heritage Investors Management Corp. Company insiders that have sold Chemours company stock in the last year include Amy Trojanowski, Mark Newman and Paul Kirsch. View Insider Buying and Selling for Chemours.

CC stock was bought by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, DNB Asset Management AS and FNY Investment Advisers LLC. Company insiders that have bought Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mark P Vergnano, Mary B Cranston, Richard H Brown and Susan M Kelliher. View Insider Buying and Selling for Chemours.

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CC stock can currently be purchased for approximately $17.46.

Chemours has a market capitalization of $2.85 billion and generates $6.64 billion in revenue each year. The specialty chemicals company earns $995 million in net income (profit) each year or $5.67 on an earnings per share basis. Chemours employs 7,000 workers across the globe.View Additional Information About Chemours.

The official website for Chemours is http://www.chemours.com/.

Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]